These three diabetes stocks should be on your radar right now.
News & Analysis: AstraZeneca
Look past the surface for these strong contenders.
These A-list drugmakers must both contend with expiring patents, new drug uncertainties, and hungry competitors. But they're in different stages of their cyclical journeys.
AZN earnings call for the period ending March 31, 2019.
Deals, downgrades, and disappointing earnings led to losses for these stocks.
These dividend stocks could send you checks for a lifetime.
Keep your eyes on these three hot diabetes stocks this month.
These aren't the largest players in the field, but they could take the lead faster than you think.
Find out how earnings helped these companies.
These income-generating businesses deserve a place in your portfolio.